Biosergen AS
About:
Biosergen AS develops variants of nystatin with improved properties.
Website: https://biosergen.net/
Top Investors: SINTEF Venture AS, Rosetta Capital
Description:
Biosergen AS develops variants of nystatin with improved properties. Its pipeline products include S44HP, an antibiotic that is more potent than nystatin against several fungal pathogens; and nystatin analogues produced through manipulation of the nystatin biosynthetic genes.
Total Funding Amount:
44.9M SEK
Headquarters Location:
Trondheim, Sor-Trondelag, Norway
Founded Date:
2004-01-01
Founders:
Number of Employees:
1-10
Last Funding Date:
2024-11-18
IPO Status:
Public
Industries:
© 2025 bioDAO.ai